Aspirin and Cancer: How Aspirin May Reduce Cancer Risk – BBC News

A recent BBC Arabic report highlights growing scientific interest in aspirin’s potential role in reducing cancer risk, particularly in certain patient groups. The article, published on April 21, 2026, discusses findings from a Newcastle University-led study suggesting that low-dose aspirin may lower the likelihood of developing or dying from specific cancers in some individuals.

The study, referenced in multiple reputable sources including BBC and University of Cambridge research, indicates that aspirin’s anti-inflammatory properties may interfere with biological processes that allow cancer cells to spread. Researchers have begun to uncover how the drug affects platelets and immune responses, potentially creating an environment less conducive to metastasis.

According to the Newcastle University-led study, not all patients benefit equally from aspirin use in cancer prevention. The protective effect appears most pronounced in individuals with certain genetic or molecular profiles, underscoring the importance of personalized approaches rather than broad recommendations.

Supporting this, research from the University of Cambridge has identified specific mechanisms by which aspirin might inhibit cancer progression. These include blocking thromboxane A2 production, which platelets use to support circulating tumor cells, and enhancing immune surveillance against malignant cells attempting to establish secondary tumors.

While observational data and clinical trials have shown associations between regular low-dose aspirin use and reduced incidence of colorectal, esophageal, and certain breast cancers, experts caution that aspirin is not without risks. Long-term use, even at low doses, can increase the likelihood of gastrointestinal bleeding and hemorrhagic stroke, particularly in older adults or those with preexisting conditions.

Major health organizations have not issued universal guidelines recommending aspirin for cancer prevention due to these safety concerns. Instead, decisions about aspirin use are typically individualized, weighing potential cardiovascular and cancer-related benefits against bleeding risks based on a patient’s medical history and risk factors.

The BBC Arabic report emphasizes that individuals should not begin taking aspirin for cancer prevention without consulting a healthcare provider. Medical professionals can assess whether the potential benefits outweigh the risks in specific cases, especially for those with Lynch syndrome, hereditary colorectal cancer risk, or a history of cardiovascular disease.

Ongoing research continues to refine understanding of which populations may benefit most from aspirin’s chemopreventive effects. Trials are investigating biomarkers that could predict response, aiming to move toward precision prevention strategies rather than one-size-fits-all recommendations.

As science advances, the focus remains on balancing promise with prudence. While aspirin’s role in cancer prevention is increasingly understood at a biological level, its use remains a clinical decision requiring professional guidance — not a self-administered remedy drawn from household medicine cabinets.